What is the effect of the combination of Alpelisib and CDK4/6?

Alpelisib (Alpelisib)-Piqray is a targeted therapy drug mainly used to treat patients with advanced breast cancer harboring PIK3CA mutations. It works by inhibiting the PI3K pathway. The PI3K signaling pathway is one of the key mechanisms in the occurrence and progression of various tumors. Especially in HER2-negative breast cancer, PIK3CA mutations have an important impact on tumor aggressiveness. Apelvis is often used in combination with the endocrine therapy fulvestrant, which has demonstrated efficacy in the treatment of metastatic or advanced breast cancer.

In recent years, the treatment regimen combiningCDK4/6 inhibitors (such aspalbociclib, rebociclib, abeciclib) and apelvis has become a new development in the field of breast cancer. CDK4/6 inhibitors inhibit the CDK4 and CDK6 proteins in the cell cycle process, prevent cancer cells from entering the S phase, slow down the proliferation of tumor cells, and thereby control the development of tumors. Clinical studies have shown that apelixin combined with CDK4/6 inhibitors can effectively enhance the therapeutic effect of breast cancer, especially in those patients with PIK3CA mutations.

The combined application of CDK4/6 inhibitors and apelvis aims to reduce drug resistance and proliferation of tumor cells through multiple targeting effects. Apelvis controls the development of cancer caused by PIK3CA mutations by inhibiting the PI3K signaling pathway, while CDK4/6 inhibitors further inhibit tumor growth by blocking the proliferation cycle of cancer cells. This treatment regimen has shown good efficacy in multiple clinical studies, especially being able to prolong the progression-free survival (PFS) of patients.

Overall, the combination of apelvis andCDK4/6 inhibitors is an important advance in the treatment of breast cancer, especially for those breast cancer patients carrying PIK3CA mutations, with good clinical prospects. Future research will further clarify the optimal scope of application of this treatment regimen and explore how to minimize side effects and improve treatment effectiveness.

Reference materials:https://go.drugbank.com/drugs/DB12015